

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPN. LTD.

Regd. Office: VIII. Chola, Bulandshahr(UP)-203203

PART I

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER AND THREE MONTHS ENDED 30.09.2015
(Rupees in lacs)

Particulars	3 months ended 30/09/2015	Preceding 3 months ended 30/06/2015	Corresponding 3 months ended 30/09/2014 in the previous year	Year to date figures for current period ended 30.09.2015	Previous year ended 31/03/2015
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1 Income from operations					
(a) Net sales/income from operations (Net off excise duty)	1,341.21	1,657.89	2,483.01	2,999.10	14,621.63
(b) Other operating income	0.00	0.00	0.00	0.00	0.00
Total income from operations (net)	1,341.21	1,657.89	2,483.01	2,999.10	14,621.63
2 Expenses					
(a) Cost of materials consumed	1,051.84	1,767.00	2,876.36	2,818.84	12,723.72
(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	267.34	(85.34)	(910.85)	182.00	(340.55)
(d) Employee benefits expense	236.71	243.31	220.67	480.02	897.87
(e) Depreciation and amortisation expense	29.04	28.69	21.15	57.73	86.87
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	161.55	157.23	398.05	318.77	601.53
Total expenses	1,746.48	2,110.89	2,605.38	3,857.36	13,969.44
3 Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	(405.27)	(453.00)	(122.37)	(858.26)	652.19
4 Other income	34.36	54.17	7.11	88.53	69.03
5 Profit/(Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	(370.91)	(398.83)	(115.26)	(769.73)	721.22
6 Finance costs	13.89	7.64	4.93	21.54	444.28
7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	(384.80)	(406.47)	(120.19)	(791.27)	276.94
8 Exceptional items	0.00	0.00	0.00	0.00	0.00
9 Profit/(Loss) from ordinary activities before tax (7 ± 8)	(384.80)	(406.47)	(120.19)	(791.27)	276.94
10 Tax expense	(137.15)	(91.61)	(36.49)	(228.76)	46.61
11 Net Profit/(Loss) from ordinary activities after tax (9 ± 10)	(247.65)	(314.86)	(83.70)	(562.51)	230.33
12 Extraordinary items (net of tax expense Rs. _____ Lakhs)	0.00	0.00	0.00	0.00	0.00
13 Net Profit/(Loss) for the period (11 ± 12)	(247.65)	(314.86)	(83.70)	(562.51)	230.33
14 Share of profit/(loss) of associates*	N.A.	N.A.	N.A.	N.A.	N.A.
15 Minority interest *	N.A.	N.A.	N.A.	N.A.	N.A.



16	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13 + 14 + 15)*	(247.65)	(314.86)	(83.70)	(562.51)	230.33
17	Paid-up equity share capital (Face Value Rs.10)	4,318.00	4,318.00	4,318.00	4,318.00	4,318.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-
19	Earnings per share (before extraordinary items) (of Rs. ___/- each) (not annualised):					
.i	(a) Basic	(0.57)	(0.73)	(0.19)	(1.30)	0.53
	(b) Diluted	(0.57)	(0.73)	(0.19)	(1.30)	0.53
19	Earnings per share (after extraordinary items) (of Rs. ___/- each) (not annualised):					
.ii	(a) Basic	(0.57)	(0.73)	(0.19)	(1.30)	0.53
	(b) Diluted	(0.57)	(0.73)	(0.19)	(1.30)	0.53

See accompanying note to the financial results

* Applicable in the case of consolidated results.

Note: The classification/disclosure of items in the financial results shall be in accordance with the Revised Schedule VI. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

PART II
Select Information for the Period Ended 30.09.2015 (Rs. In Lacs)

	Particulars	3 months ended 30/09/2015	Preceding 3 months ended 30/06/2015	Corresponding 3 months ended 30/09/2014 in the previous year	Year to date figures for current period ended 30.09.2015	Previous year ended 31/03/2015
A1	PARTICULARS OF SHAREHOLDING					
	Public shareholding					
	- Number of shares	17,594,000	17,594,000	17,594,000	17,594,000	17,594,000
	- Percentage of shareholding	40.75	40.75	40.75	40.75	40.75
2	Promoters and Promoter Group Shareholding					
	(a) Pledged/Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
	(b) Non - encumbered					
	- Number of shares	25,586,000	25,586,000	25,586,000	25,586,000	25,586,000
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	59.25	59.25	59.25	59.25	59.25
B	Particulars	3 months ended				



	(30/09/2015)
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter.	0.00
Received during the quarter.	2.00
Disposed of during the quarter.	2.00
Remaining unresolved at the end of the quarter.	0.00

SEGMENT REPORTING

	Particulars	3 months ended 30/09/2015	Preceding 3 months ended 30/06/2015	Corresponding 3 months ended 30/09/2014 in the previous year	Year to date figures for current period ended 30.09.2015	Previous year ended 31/03/2015
1	SEGMENT REVENUE					
	Oral Polio Vaccine	1,341.21	1,657.35	2,454.99	2,998.56	14,593.24
	Zinc Dispersible Tablets	0.00	0.54	28.02	0.54	28.39
	Less: Inter Segment Revenue	-	-	-	-	-
	Net Sales/Income from Operations	1,341.21	1,657.89	2,483.01	2,999.10	14,621.63
2	SEGMENT RESULTS (Profit Before Tax)					
	Oral Polio Vaccine	(371.42)	(396.92)	(111.45)	(768.34)	314.73
	Zinc Dispersible Tablets	(13.38)	(9.55)	(8.74)	(22.93)	(37.79)
	Less: Other unallocable expenditure net off unallocable income	-	-	-	-	-
	Total Profit Before Tax	(384.80)	(406.47)	(120.19)	(791.27)	276.94
3	CAPITAL EMPLOYED (Segment Assets less Liabilities)					
	Oral Polio Vaccine	3,711.17	3,845.04	4,418.03	3,711.17	4,331.15
	Zinc Dispersible Tablets	(142.31)	(129.31)	(164.00)	(142.31)	(123.94)
	Others	-	-	-	-	-
	Total Capital Employed	3,568.86	3,715.73	4,254.03	3,568.86	4,207.20

NOTES :-

- Accounting for Employees Benefit has been made as per AS 15 on estimated basis as actuarial valuation will be carried out at the end of the year.
- There is no related party in terms of AS 18 issued by ICAI.
- The EPS has been calculated as per AS 20 issued by ICAI.
- No provision for impairment has been made in the current quarter/period as on date.
- Interest earned on capital grant received from Govt. of India for projects have credited to the grant account as per the terms of the grant.
- The company is currently engaged in production of Oral Polio Vaccine and Zinc Dispersible Tablets.
- Facilities for the production of Zinc Dispersible Tablets have been created out of the grant received from Govt. of India, Deptt. of Biotechnology, Ministry of Science & Technology. Segment Capital Employed for the production of Zinc Dispersible Tablets have been taken at Nil, however added the profit/loss earned/incurred during the previous years and the period being reported upon to the Segment Capital Employed for Zinc DT.



(Handwritten signature)

8 Closing stock of raw material and finished goods for the quarter ending 30th September, 2015 is as under :

	Unit	Qty.	Amount (Rs. In lacs)
Raw Material			
Zinc Sulphate Monohydrate, Aspartame, Micro Crystalline Cellulose, Aerocil, etc (Zinc Tablets)	combined	-	4.08
O.R.S. Sachet and raw material for Combo Kit	Nos.	411590	9.87
Oral Polio Vaccine Bulk (Type-I)	m.doses	50.71	1,147.90
Oral Polio Vaccine Bulk (Type-II)	m.doses	62.66	305.90
Oral Polio Vaccine Bulk (Type-III)	m.doses	51.40	751.78
Total Raw Material			2,219.53
Finished Goods			
Zinc Tablets	Nos	974708	5.22
Diarrhea Management Kits	Nos.	6361	0.93
Oral Polio Vaccine	Vials	1122581	1,072.12
Total Finished Goods			1,078.26

9 Detail of supply/sale made/to be made during the financial year 2015-16 is as under :-

Total Orders/Supplies to be made 2015-16		Supplied/Sale (01.04.15 to 30.09.2015)		Balance Supply/Sale in F.Y. 2015-16	
Qty	Value (including VAT, Excise and Freight) (Amount in Rupees)	Qty	Value (including VAT, Excise and Freight) (Amount in Rupees)	Qty	Value (including VAT, Excise and Freight) (Amount in Rupees)
Zinc Tablets (Nos.)					
86,002	63,001	86,002	63,001	0	0
Diarrhea Management Kits (Nos.)					
0	0	0	0	0	0
Oral Polio Vaccine (Million Doses)					
260.63 (tOPV)	1,442,050,741	61.128	305,259,504	199.50	1,136,791,237
39.17 (bOPV)	219,226,902	1.667	9,583,152	37.50	209,643,750
299.80 (tOPV + bOPV)	1,661,277,643	62.795	314,842,656	237.00	1,346,434,987
Total	1,661,340,644		314,905,657		1,346,434,987

10 Previous year/quarter figures have been regrouped/re-arranged wherever necessary

Place: New Delhi
Date: 06.11.2015



(Signature)
(Veena T. Bhatia)
Managing Director

Annexure-IX of clause 41 shall be substituted with the following

(Rs.in lacs)

Clause 41 of the Listing Agreement for Companies (Other than Bank)

Standalone/ Consolidated Statement of the Assets and Liabilities Particulars		As at 30.09.2015	As at (Current year end) 31.03.2015
A	EQUITY AND LIABILITIES		
1	Shareholder's funds		
	(a) Share Capital	4318.00	4318.00
	(b) Reserve and surplus	(749.14)	(186.54)
	(c) Money received against share warrents		
	Sub total -Shareholders' funds	3568.86	4131.46
2	Share application money pending allotment	-	-
3	Minority Interest	-	-
4	Non-current liabilities		
	(a) Long- term borrowings	-	-
	(b) Deffered tax liabilities (net)	0.00	28.31
	(c) Long term provision	339.57	332.00
	Sub-total Non-Current Liabilities	339.57	360.31
5	Current liabilities		
	(a) Short-term borrowings	1775.61	-883.82
	(b) Trade payables	2114.92	3126.28
	(c) Other current liabilities	616.19	1237.94
	(d) Short- term provisions	0.00	54.26
	Sub-total-Current Liabilities	4506.72	3534.66
	TOTAL-EQUITY AND LIABILITIES	8415.14	8026.43
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	553.35	605.35
	(b) Goodwill on consolidation	0.00	0.00
	(c) Non-current investments	0.00	0.00
	(d) Deffered tax assets (net)	200.45	0.00
	(e) Long term loan and advances	0.00	40.10
	(f) Other non current assets	21.93	21.93
	Sub total - Non Current Assets	775.74	667.38
2	Current assets		
	(a) Current investments	0.00	0.00
	(b) Inventories	3513.93	2564.50
	(c) Trade receivables	2156.57	1369.76
	(d) Cash and cash equivalents	1522.71	3026.26
	(e) Short term loan and advances	370.34	365.36
	(f) Other current assets	75.85	33.17
	Sub total - Current Assets	7639.40	7359.05
	TOTAL -ASSETS	8415.14	8026.43



(Uttam Kumar Singh)
CFO

